View Clinical Trial (Medical Research Study)
Non-Invasive Determination of Fetal Chromosome Abnormalities
| City: |
|
Burlington |
| State: |
|
Vermont |
| Zip Code: |
|
05405 |
| Conditions: |
|
Down Syndrome (Trisomy 21) - Edward's Syndrome (Trisomy 18) - Patau Syndrome (Trisomy 13) - Klinefelter Syndrome (47, XXY) - and Other Chromosome - Abnormalities. |
| Purpose: |
|
The overall significance of this study is to develop a laboratory developed test (LDT) to
use a new marker in the maternal blood to better identify pregnancies that have a child with
a chromosome abnormality such as Down syndrome (trisomy 21), Edward's syndrome (trisomy 18),
Patau syndrome (trisomy 13), Klinefelter syndrome, (47, XXY), and other chromosome
abnormalities. Accomplishing that task would reduce the need for invasive amniocentesis and
CVS procedures.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- This study is only applicable to women who are between 8 and 30 weeks' gestation and
who have been determined increased risk for fetal aneuploidy. In the interest of
expediting and simplifying this study, the investigators want only women who have
already decided to undergo second-trimester amniocentesis or CVS.
Exclusion Criteria:
- The only exclusion criteria are those mentioned.
|
| NCT ID: |
|
NCT00891852 |
| Primary Contact: |
|
Principal Investigator Stephen A Brown, MD Lenetix, Inc.
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Burlington, Vermont 05405 United States
Stephen A Brown, MD Phone: 802-656-4775 Email: stephen.brown@uvm.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 25, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|